Bąkowski Wojciech, Śmiechowicz Jakub, Lemańska-Perek Anna, Dragan Barbara, Goździk Waldemar, Adamik Barbara
Clinical Department of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland.
Department of Chemistry and Immunochemistry, Wroclaw Medical University, M. Sklodowskiej-Curie 48/50, 50-369 Wroclaw, Poland.
J Clin Med. 2025 May 16;14(10):3493. doi: 10.3390/jcm14103493.
: Hemolysis during sepsis may be driven by patient-specific factors, including the intensity of the inflammatory response and the etiology of infection, as well as treatment-related factors, such as the use of extracorporeal life-support devices. : We evaluated the incidence of hemolysis-reflected by decreased plasma levels of haptoglobin and hemopexin-in a cohort of septic patients with acute respiratory failure ( = 50) admitted to the intensive care unit (ICU). : Hemolysis was observed in 60% of patients. Its incidence was significantly higher among those with septic shock (86%) and those receiving extracorporeal membrane oxygenation (ECMO) therapy (81%). While continuous renal replacement therapy (CRRT) alone did not increase the incidence of hemolysis, its combination with ECMO was associated with hemolysis in 100% of those treated. Logistic regression analysis identified low haptoglobin levels (odds ratio [OR] 27.1), advanced age (OR 1.2), and stage 3 acute kidney injury (OR 22.2) as significant predictors of mortality. : These findings highlight the clinical relevance of monitoring hemolysis in septic patients. Given the routine availability of haptoglobin and hemopexin assays in most hospital laboratories, these biomarkers offer practical and accessible tools for the detection and monitoring of hemolysis in critically ill patients.
脓毒症期间的溶血可能由患者特异性因素驱动,包括炎症反应的强度和感染病因,以及与治疗相关的因素,如体外生命支持设备的使用。我们评估了入住重症监护病房(ICU)的一组急性呼吸衰竭脓毒症患者(n = 50)中溶血的发生率,通过血浆触珠蛋白和血红素结合蛋白水平降低来反映。60%的患者观察到溶血。在感染性休克患者(86%)和接受体外膜肺氧合(ECMO)治疗的患者(81%)中,其发生率显著更高。虽然单独的连续性肾脏替代治疗(CRRT)并未增加溶血发生率,但CRRT与ECMO联合治疗的患者中100%出现溶血。逻辑回归分析确定低触珠蛋白水平(比值比[OR] 27.1)、高龄(OR 1.2)和3期急性肾损伤(OR 22.2)是死亡率的显著预测因素。这些发现突出了监测脓毒症患者溶血的临床相关性。鉴于大多数医院实验室常规可获得触珠蛋白和血红素结合蛋白检测,这些生物标志物为危重症患者溶血的检测和监测提供了实用且可及的工具。